Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors

Abstract

Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.

What is claimed is: 
     
         1 . A compound for treating bacteria, comprising a disugar or disaccharide hydrocarbon selected from the group consisting of benzyl decyl β-maltoside (BDeβM) and benzyl dodecyl β-maltoside (BDβM), 4-tertiary butyl benzyl decyl β-maltoside (4-tBuBDeβM) and 4-tertiary butyl benzyl dodecyl β-maltoside (4-tBuBDβM), 3,5-dimethyl benzyl dodecyl β-maltoside (3,5-DMBDβM), 4-methyl benzyl dodecyl β-maltoside (4-MBDβM), benzophenonyl decyl β-maltoside (BPDeβM), adamantane dodecyl β-maltoside (ADβM) and 12-hydroxy decyl β-maltose (12-HODeβM), dodecyl-β-cellobioside (DβC), dodecyl-β-lactoside (DβL), dodecyl-α-rhamnoside (DαR), β-cyclodextrin (βCD), dodecyl-βCD-squarate (DβCDS), decyl-β-cellobioside (DeβC), undecyl-β-cellobioside (UβC), tridecyl-β-cellobioside (TβC), dodecyl-β-maltoside (DβM), saturated farnesyl-β-maltoside (SFβM), dodecyl-β-cellobioside (DβC), decyl-β-cellobioside (DeβC), (UβC), tridecyl-β-cellobioside (TβC), dodecyl-α-cellobioside (DαC), undecylenyl-β-cellobioside (UDβC), farnesyl-β-cellobioside (FβC), saturated farnesyl-β-cellobioside (SFβC), saturated farnesyl-α-cellobioside (SFαC), 2-octyl-dodecyl-β-cellobioside (2-ODβC), 2-octyl-dodecyl-α-cellobioside (2-ODαC), dodecyl-β-lactoside (DβL), saturated farnesyl-β-lactoside (SFβL). 
     
     
         3 . The compound of  claim 1 , wherein the structure of the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         3 . The compound of  claim 1 , wherein the structure of the compound is selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         4 . A method of treating a bacterial infection, comprising the step of administering an effective amount of dodecyl-β-maltoside (DβM). 
     
     
         5 . The method of  claim 4 , wherein the bacterial infection is a complication of cystic fibrosis. 
     
     
         6 . The method of  claim 4 , wherein the step of administering an effective amount of dodecyl-β-maltoside (DβM) comprises the step of administering the effective amount of dodecyl-β-maltoside (DβM) via a nebulizer. 
     
     
         7 . The method of  claim 6 , further comprising the step of administering an effective amount of an antibiotic. 
     
     
         8 . The method of  claim 7 , wherein the step of administering an effective amount of an antibiotic comprises the step of administering the effective amount of an antibiotic via a nebulizer. 
     
     
         9 . The method of  claim 8 , wherein the steps of administering an effective amount of dodecyl-β-maltoside (DβM) and administering an effective amount of an antibiotic are performed sequentially. 
     
     
         10 . The method of  claim 9 , wherein the steps of administering an effective amount of dodecyl-β-maltoside (DβM) and administering an effective amount of an antibiotic are performed at the same time. 
     
     
         11 . A method of addressing a bacterial population, comprising the step of exposing the bacterial population to an effective amount of the compound of  claim 1 . 
     
     
         12 . The method of  claim 11 , wherein the bacterial population has formed a biofilm. 
     
     
         13 . The method of  claim 11 , wherein the bacterial population has not formed a biofilm. 
     
     
         14 . The method of any one of  claim 11 ,  12  or  13 , wherein the compound comprises dodecyl-β-maltoside. 
     
     
         15 . The method of any one of  claim 11 ,  12  or  13 , wherein the bacterial population comprises an infection. 
     
     
         16 . The method of  claim 15 , wherein the infection is associated with cystic fibrosis. 
     
     
         17 . The method of  claim 11 , further comprising the step of the step of exposing the bacterial population to an effective amount of an antibiotic. 
     
     
         18 . The method of  claim 17 , wherein either or both of the step of administering an effective amount of the compound of  claim 1  and the step of administering an effective amount of an antibiotic is performed using a nebulizer.